Oxeia-biopharma

Millions Suffer from Concussion. Zero Treatments.

Oxeia Biopharma is developing what could be the first FDA-approved treatment for persistent concussion symptoms. 85% responder rate in Phase 2a. Backed by NFL quarterback Alex Smith (Director and Investor) and cornerback Richard Sherman (Advisor).

INVEST

Share Price

$0.79

Min Investment

$499.28

This Reg CF offering is made available through StartEngine Primary, LLC, a member of FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

OXE103 is an investigational therapy subject to regulatory review and clinical development risk. Statements regarding regulatory approval, clinical development timelines, market opportunity, and potential outcomes are forward-looking and involve risks and uncertainties. Actual results may differ materially.

Learn More About Our Mission

Thank you for signing up to receive Oxeia Biopharma Updates!

Oops! Something went wrong while submitting the form.

By clicking “Learn More”, you consent to receive marketing communications including text messages and emails (e.g., promotions, cart reminders, funding updates) from StartEngine Crowdfunding, Inc. using the contact information you provide. You understand and agree that messages may be sent using an autodialer or automated systems. Consent is not a condition of purchase. Message and data rates may apply; message frequency varies. You may unsubscribe from email communications at any time by clicking the unsubscribe link in the email, and from text messages by replying STOP. For more information, see our Privacy Policy & Terms.

The opportunity

Imagine A World Where Concussion Patients Have Real Treatment Options

Alex Smith played through multiple concussions during his NFL career. He famously lost his starting job for the 49ers after a concussion sidelined him. Part of why Smith fought through the pain was competitive fire. But the bigger reason was practical: there are no FDA-approved treatments for concussions.

Oxeia’s phase 2a trial at University of Kansas Medical Center demonstrated an 85% responder rate among patients with persistent concussion symptoms.
 

INVEST

team

$9 Billion in Prior Exits

AMIT MUNSHI

Founder

Served as President and CEO of Arena Pharmaceuticals from 2016 until its $6.7 billion acquisition by Pfizer in 2022. At Arena, he advanced multiple drug candidates through clinical development, including etrasimod (now Velsipity) for ulcerative colitis. Previously held leadership roles at Amgen, Kythera Biopharmaceuticals (acquired by Allergan for $2.1 billion), and Percivia (acquired by Johnson & Johnson). Brings 25+ years of experience in clinical development and portfolio management.

KARTIK SHAH

Director & Founder

Co-founded Oxeia and negotiated the licensing agreement that secured access to over $100+ million in completed preclinical, manufacturing, and clinical development data generated by Daiichi Sankyo. Led Oxeia's fundraising and operations, overseeing strategy, licensing, and intellectual property. Previously held commercial strategy roles at Atara Biotherapeutics and corporate strategy and post-merger positions at Amgen. He currently serves as Chief Business Officer at Tactile Therapeutics, a discovery stage neuroscience company.

DR. MICHAEL WYAND

Chief Executive Officer, Principal Accounting Officer, Director

Led drug development programs at Epirus, BioAssets, and Therion Biologics, where he advanced Prostvac through Phase 2 clinical development. Brings 30 years of experience navigating FDA regulatory pathways and positioning biotech companies for strategic exits. His expertise spans early clinical trials through commercialization across multiple therapeutic areas.

DR. VISHAL BANSAL

Chief Scientific Officer, Inventor & Founder

Trauma surgeon at Scripps Mercy Hospital in San Diego and inventor of OXE103. His research at UCSD, the American Association of Trauma (AAST), and the American Surgical Association (ASA) discovered that ghrelin, a naturally occurring peptide hormone, reduces oxidative stress, prevents blood-brain barrier breakdown, and restores neural function following traumatic brain injury. Published in Journal of Neurotrauma, Brain Research, Inflammation, and Journal of Surgical Research, with clinical studies published in Neurotrauma Reports.

Board & Advisors

ALEX SMITH

Director, Investor & Advisor

16-year NFL career. 3× Pro Bowl. 2020 NFL Comeback Player of the Year. ESPN analyst. Suffered a career-altering concussion in 2012 that cost him his starting position with the San Francisco 49ers. After witnessing teammates struggle with persistent post-concussion symptoms for months and years—with no treatment options available—he joined Oxeia as both investor and board member to help bring potentially the first FDA-approved therapy to market.

TED RAAD

Director

Former CEO of Pulmatrix, a clinical-stage biopharmaceutical company developing inhaled therapies for respiratory diseases. Previously served as Chief Commercial Officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation's largest independent home infusion provider. Earlier held senior commercial positions at Sunovion, launching multiple respiratory and central nervous system products and establishing strategic alliances in the US and Japan.

RICHARD SHERMAN

Advisor

11-year NFL veteran. 5× Pro Bowl. 3× All-Pro. Super Bowl XLVIII Champion. Sustained a concussion during his 2011 rookie season and played through blurred vision—a decision he has since said he regrets. Now serves as one of the NFL's most vocal advocates for brain health and player safety, joining Oxeia to help advance the potential first treatment for persistent concussion symptoms.

DR. GERALD GRANT

Clinical Advisor

Chair of the Department of Neurosurgery at Duke University School of Medicine. NIH-funded investigator with active research programs in brain tumors, focused ultrasound, and concussion. Previously served as chief of pediatric neurosurgery at Stanford and as U.S. Air Force combat neurosurgeon deployed to Iraq during Operation Iraqi Freedom. Author of over 300 peer-reviewed publications.

Dr. Murray Stein

Clinical Advisor

Distinguished Professor of Psychiatry and Family & Preventive Medicine at University of California San Diego (UCSD) and Vice Chair for Clinical Research in Psychiatry. Staff Psychiatrist at VA San Diego Healthcare System and Director of the Anxiety & Traumatic Stress Disorders Program. Principal Investigator and Director of the Department of Defense-funded INTRuST Consortium, which conducts research on treatments for PTSD and traumatic brain injury in veterans. Published over 800 peer-reviewed articles in journals including NEJM, Lancet, and JAMA. Member of the FDA Psychopharmacologic Drugs Advisory Committee.

Dr. Chris Nowinski

Advisor

Co-founder and CEO of the Concussion & CTE Foundation. Former Harvard football player and WWE professional wrestler who developed career-ending post-concussion syndrome in 2003. Authored Head Games: Football's Concussion Crisis (2006), which documented the NFL's systematic minimization of concussion risks. Co-founded Boston University's CTE Center and UNITE Brain Bank, the world's largest resource for CTE research. Earned his doctorate in Behavioral Neuroscience from Boston University and has published over 50 scientific papers.

Dr. Michael Rippee

Principal Investigator of Phase 2a Clinical Study

Associate Professor of Neurology at University of Kansas Medical Center and Medical Director of the Center for Concussion Management at The University of Kansas Health System. Principal Investigator for Oxeia's Phase 2a study, which demonstrated an 85% responder rate in persistently symptomatic concussion patients. Sports neurologist specializing in concussion treatment and long-term brain health optimization in athletes. Research focuses on novel treatments, sleep disturbances following concussion, and interdisciplinary care approaches.

Bringing the FDA-Approved Treatment to Market

Oxeia is developing what could be the first FDA-approved treatment for persistent concussion symptoms. With an 85% responder rate in Phase 2a, access to $100M+ in development data, and a team with $9 billion in prior exits, we believe there's a real path to market. Phase 2b enrollment begins in 2026. Data readout expected approximately 24 months after funding closes.  

INVEST

Learn More About Our Mission

Thank you for signing up to receive Oxeia Biopharma Updates!

Oops! Something went wrong while submitting the form.

PERKS

earn bonus shares

Your belief in our vision deserves more, and in recognition of that support, we are extending a limited-time package of premium perks.

Loyalty Bonus: All existing shareholders will receive 25% bonus shares.

Time-based perks

FLASH PERK 1

Invest $2,500+ between days 35 - 40 and receive 12% bonus shares.

INVEST

FLASH PERK 2

Invest $2,500+ between days 60 - 65 and receive 10% bonus shares.

INVEST

Amount-Based Perks

Tier 1

Invest $500+ and receive 3% bonus shares.

INVEST

Tier 2

Invest $1,000+ and receive 5% bonus shares.

INVEST

Tier 3

Invest $5,000+ and receive 7% bonus shares.

INVEST

Tier 4

Invest $10,000+ and receive 10% bonus shares + invitation to an exclusive webinar.

INVEST

Tier 5

Invest $20,000+ and receive 15% bonus shares.

INVEST

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

Crowdfunding investments made through a self-directed IRA cannot receive non-bonus share perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those non-bonus share perks because they would be receiving a benefit from their IRA account.

The 10% StartEngine Venture Club Bonus

Oxeia Biopharmaceuticals, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series CF Preferred Stock at $0.79/ share, you will receive 110 shares of Series CF Preferred Stock, meaning you’ll own 110 shares for $79. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club Bonus and the Loyalty Bonus in addition to the aforementioned bonus.

LEGAL DISCLAIMER
Certain statements on this page may constitute forward-looking statements, including statements regarding regulatory approval, clinical development timelines, market opportunity, and potential outcomes. These statements involve risks and uncertainties, and actual results may differ materially.
‍
OXE103 is an investigational therapy subject to regulatory review and clinical development risk. Team members' prior experience is provided for background purposes only and is not indicative of future results. Certain statements on this page may constitute forward-looking statements, including statements regarding regulatory approval, clinical development timelines, market opportunity, and potential outcomes. These statements involve risks and uncertainties, and actual results may differ materially.

Alex Smith serves as a director and Advisor of the Company and receives compensation from the Company in that role. His participation should not be considered an endorsement of the investment opportunity.
‍

This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

INVEST